Thrombocytosis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 63: Line 63:
* Vascular occlusive events and [[Bleeding|hemorrhages]]
* Vascular occlusive events and [[Bleeding|hemorrhages]]
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Flushing
| align="center" style="background:#F5F5F5;" + |
* Flushing
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
Line 107: Line 108:
* Ashkenazi Jewish descent
* Ashkenazi Jewish descent
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Facial plethora
| align="center" style="background:#F5F5F5;" + |
* Facial plethora
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |Nl
Line 148: Line 150:
* Chemicals exposure
* Chemicals exposure
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |[[Pallor]]
| align="center" style="background:#F5F5F5;" + |
* [[Pallor]]
 
* [[Bruising]]
* [[Bruising]]
* [[Nodules|Skin nodules]]
* [[Nodules|Skin nodules]]
Line 508: Line 512:
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* History of  close contact
* History of  close contact
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Acutely ill
* Acutely ill
Line 542: Line 546:
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Family history of  
* Family history of rheumatologic isorders
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Acutely ill
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Nl
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |-
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* [[Arthritis]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Microcytic anemia
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Depends on the type
| align="center" style="background:#F5F5F5;" + |Clinical manifestation+ culture
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Depends on the type
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
|-
|-
! align="center" style="background:#DCDCDC;" + |[[Acute pancreatitis]]
! align="center" style="background:#DCDCDC;" + |[[Acute pancreatitis]]
Line 569: Line 580:
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |Any but more in elderly
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* [[Long-term effects of alcohol|Alcohol consumption]]
* [[Long-term effects of alcohol|Alcohol consumption]]
* [[Gallstone disease|Gallstone]]
* [[Gallstone disease|Gallstone]]
* [[Hyperlipoproteinemia|Hypertriglyceridemia]]
* [[Hyperlipoproteinemia|Hypertriglyceridemia]]
* [[Obesity]]
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
Line 582: Line 594:
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Abdominal tenderness
* [[Tenderness (medicine)|Abdominal tenderness]]
* N/V
* [[Nausea and vomiting|N/V]]
* [[Dyspnea]]
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |Nl to ↓
Line 594: Line 607:
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Diffusely enlarged and hypoechoic [[pancreas]] on abdominal [[ultrasound]]
* Focal or diffuse enlargement of the [[pancreas]] with heterogeneous enhancement on abdominal [[Computed tomography|CT scan]]
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |Clinical manifestation
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Rarely progress to severe [[inflammation]] and [[necrosis]]
* '''Organ failure'''
|-
|-
! align="center" style="background:#DCDCDC;" |[[Cancer|Malignancy]]
! align="center" style="background:#DCDCDC;" |[[Cancer|Malignancy]]<ref name="YangJiang2018">{{cite journal|last1=Yang|first1=Chen|last2=Jiang|first2=Hui|last3=Huang|first3=Shaozhuo|last4=Hong|first4=Hui|last5=Huang|first5=Xiaowen|last6=Wang|first6=Xiaojie|last7=Liao|first7=Weixin|last8=Wang|first8=Xueyi|last9=Chen|first9=Xuewen|last10=Jiang|first10=Liming|title=The prognostic role of pretreatment thrombocytosis in gastric cancer|journal=Medicine|volume=97|issue=31|year=2018|pages=e11763|issn=0025-7974|doi=10.1097/MD.0000000000011763}}</ref>
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
* Accelerated [[platelet]] release
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | +
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |±
| align="center" style="background:#F5F5F5;" + |Any
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Prior malignancy
* Exposure to chemicals
* Family history of malignancy
| align="center" style="background:#F5F5F5;" + |+
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Cachectic
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |Depends on the type
| align="center" style="background:#F5F5F5;" + | -
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Tenderness
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |Nl to ↓
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Microcytic anemia
* [[Myelofibrosis|Megakaryocytic]] fragments
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Proliferation of [[Megakaryocyte|megakaryocytes]]
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |Nl to ↑
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Depends on the type
| align="center" style="background:#F5F5F5;" + |[[Biopsy]]
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
| align="center" style="background:#F5F5F5;" + |
* Potential effective predictor of overall survival
| align="center" style="background:#F5F5F5;" + |
* [[Venous thromboembolism]]
| align="center" style="background:#F5F5F5;" + |
|-
|-
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Condition

Revision as of 16:49, 31 August 2018

Thrombocytosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Thrombocytosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombocytosis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Thrombocytosis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombocytosis differential diagnosis

CDC on Thrombocytosis differential diagnosis

Thrombocytosis differential diagnosis in the news

Blogs on Thrombocytosis differential diagnosis

Directions to Hospitals Treating Thrombocytosis

Risk calculators and risk factors for Thrombocytosis differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]

Overview

Thrombocytosis Differential Diagnosis

Differentiating the diseases that can cause thrombocytosis :

Category Condition Etiology Mechanism Inherited Acquried Clinical manifestations Para−clinical findings Gold standard Associated findings
Demography History Symptoms Signs
Lab Findings Imaging
Fever Appearance Bleeding BP Splenomegaly Jaundice Other CBC PBS Bone marrow exam PT PTT
Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Plt HB WBC
Autonomous thrombocytosis Hematologic malignancies Essential thrombocythemia[1]
  • Acquired mutation of JAK2, CALR, or MPL
+ - - - + Mean age >60 years old, female > male ±
  • Flushing
+ Nl + - ↑↑
  • Increased cellularity
  • Hyperplasia and clustering of megakaryocytes
  • Bone marrow reticulin may be increased with no collagen fibrosis
Nl Nl Bone marrow biopsy
  • Thrombo-hemorrhagic complications
Polycythemia vera[2]
  • Acquired mutation of JAK2
+ - - - + Mean age >60 years old -
  • Facial plethora
± Nl + - ↑↑ Bone marrow biopsy
  • Thrombo-hemorrhagic complications
Primary myelofibrosis[3] + - - - + Mean age >60 years old, male> female - + Nl + + ↑/↓ Bone marrow biopsy
  • Thrombo-hemorrhagic complications
  • Variable risk for development of acute leukemia
Chronic myeloid leukemia[4] + - - - + Mean age >50 years old, male> female History of exposure to: + + Nl + -
  • Immature leukocytes
  • Leukemic blasts
  • Leukoerythroblastic features
  • Giant platelets
  • Blast crisis
  • ↑ Proportion of metamyelocytes and other white blood cells at various stages of maturation
Bone marrow biopsy
  • Increase of immature myeloid cells
Acute myeloid leukemia[5]
  • Unknown
+ - - - + Median age of 63 years old + + Nl + + ↑/↓ ↑/↓
  • Leukemic blasts
  • Leukoerythroblastic features
  • Giant platelets
  • "Dry tap" on aspiration
  • Leukemic cells
NA Bone marrow examination + clinical manifestation
Myelodysplastic syndromes[6]
  • Unknown
  • Mutation
+ - - -/+ + Elderly Exposure to +/- Petechiae, purpura, diffuse erythematous rash + Nl + + ↑/↓
  • Large platelets
  • Ovalomacrocytosis
  • Basophilic stippling
  • Howell-Jolly body
  • Pelger-Huet anomaly
  • Ring sideroblasts
Nl Nl NA Bone marrow examination + clinical manifestation
Condition Etiology Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Inherited Acquried Demography History Fever Appearance Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT Imaging Gold standard Associated findings
Familial thrombocytosis[7][8]
  • Mutation in TPO and MPL
+ - - + - Rare familial disease, middle age male and female
  • Family history of thrombocytosis
- Normal - Nl - - - Nl Nl Nl Nl NA Genetic study
Reactive thrombocytosis Anemia/

blood loss[9]

+ - - - + Any - + Nl to ↓ - - Depends on the etilogy Nl Nl Nl NA Clinical manifestation
  • Required iron studies
Infection Chronic infections + + - - + Any + ± Nl to ↓ - ± Depends on the etilogy Nl Nl
  • Depends on the etiology
Culture Depends on the etilogy
Tuberculosis + + - - + Any
  • History of close contact
+
  • Cachectic
- Nl - - Nl Nl Nl
  • Cavitation on chest imaging
Clinical manifestation+ culture
Acute bacterial and viral infections + + - - + Any
  • History of close contact
+
  • Acutely ill
- Nl - - Depends on the etilogy Nl Nl
  • Depends on the etiology
Clinical manifestation+ culture
  • Depends on the etiology
Inflammation Vasculitides[10]
  • Unknown
+ + - ± + Any
  • Family history of rheumatologic isorders
+
  • Acutely ill
+ Nl - - Nl to ↓ Nl to ↑ Nl to ↑
  • Depends on the type
Clinical manifestation+ culture
  • Depends on the type
Acute pancreatitis + + - - + Any +
  • Acutely ill
- Nl to ↓ - + Nl to ↓ Nl to ↑ Nl to ↑ Clinical manifestation
Malignancy[11] + + - ± ± Any
  • Prior malignancy
  • Exposure to chemicals
  • Family history of malignancy
+
  • Cachectic
- Nl to ↓ Depends on the type -
  • Tenderness
Nl to ↓ Nl to ↑ Nl to ↑
  • Depends on the type
Biopsy
Condition Etiology Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Inherited Acquried Demography History Fever Appearance Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT Imaging Gold standard Associated findings
Tissue damage Thermal burns
Trauma
Myocardial infarction
Medication Myelosuppressive agents
Vincristine
Epinephrine, glucocorticoids
Interleukin-1B
All-trans retinoic acid
Thrombopoietin
Other Post-splenectomy or functional asplenia +
  • Howell-Jolly bodies
  • Nucleated RBCs
Allergic reactions
Exercise
Pseudothrombocytosis Mixed cryoglobulinemia
Cytoplasmic fragments
Category Condition Etiology Increased megakaryocyte proliferation Accelerated platelet release Reduced platelet turnover Inherited Acquried Demography History Fever Appearance Bleeding BP Splenomegaly Jaundice Other signs Plt HB WBC PBS Bone marrow exam PT PTT Imaging Gold standard Associated findings

References

  1. Brière, Jean B (2007). Orphanet Journal of Rare Diseases. 2 (1): 3. doi:10.1186/1750-1172-2-3. ISSN 1750-1172. Missing or empty |title= (help)
  2. Arber, D. A.; Orazi, A.; Hasserjian, R.; Thiele, J.; Borowitz, M. J.; Le Beau, M. M.; Bloomfield, C. D.; Cazzola, M.; Vardiman, J. W. (2016). "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia". Blood. 127 (20): 2391–2405. doi:10.1182/blood-2016-03-643544. ISSN 0006-4971.
  3. Tefferi, Ayalew; Lasho, Terra L.; Jimma, Thitina; Finke, Christy M.; Gangat, Naseema; Vaidya, Rakhee; Begna, Kebede H.; Al-Kali, Aref; Ketterling, Rhett P.; Hanson, Curtis A.; Pardanani, Animesh (2012). "One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience". Mayo Clinic Proceedings. 87 (1): 25–33. doi:10.1016/j.mayocp.2011.11.001. ISSN 0025-6196.
  4. Thompson, Philip A.; Kantarjian, Hagop M.; Cortes, Jorge E. (2015). "Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015". Mayo Clinic Proceedings. 90 (10): 1440–1454. doi:10.1016/j.mayocp.2015.08.010. ISSN 0025-6196.
  5. Rose-Inman, Hayley; Kuehl, Damon (2014). "Acute Leukemia". Emergency Medicine Clinics of North America. 32 (3): 579–596. doi:10.1016/j.emc.2014.04.004. ISSN 0733-8627.
  6. Natelson, Ethan A.; Pyatt, David (2013). "Acquired Myelodysplasia or Myelodysplastic Syndrome: Clearing the Fog". Advances in Hematology. 2013: 1–11. doi:10.1155/2013/309637. ISSN 1687-9104.
  7. Ding, J. (2004). "Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin". Blood. 103 (11): 4198–4200. doi:10.1182/blood-2003-10-3471. ISSN 0006-4971.
  8. Wiestner, A.; Padosch, S. A.; Ghilardi, N.; Cesar, J. M.; Odriozola, J.; Shapiro, A.; Skoda, R. C. (2000). "Hereditary thrombocythaemia is a genetically heterogeneous disorder: exclusion of TPO and MPL in two families with hereditary thrombocythaemia". British Journal of Haematology. 110 (1): 104–109. doi:10.1046/j.1365-2141.2000.02169.x. ISSN 0007-1048.
  9. Kuter, David J. (1996). "The Physiology of Platelet Production". Stem Cells. 14 (S1): 88–101. doi:10.1002/stem.5530140711. ISSN 1066-5099.
  10. Hamblin T, Oscier D (September 1978). "Polyarteritis presenting with thrombocytosis and palliated by plasma exchange". Postgrad Med J. 54 (635): 615–7. PMC 2425233. PMID 82963.
  11. Yang, Chen; Jiang, Hui; Huang, Shaozhuo; Hong, Hui; Huang, Xiaowen; Wang, Xiaojie; Liao, Weixin; Wang, Xueyi; Chen, Xuewen; Jiang, Liming (2018). "The prognostic role of pretreatment thrombocytosis in gastric cancer". Medicine. 97 (31): e11763. doi:10.1097/MD.0000000000011763. ISSN 0025-7974.